LLY

1,075.18

+0.27%↑

JNJ

207.23

+0.6%↑

ABBV

227.72

+0.26%↑

UNH

325.11

-0.71%↓

AZN

91.53

+0.2%↑

LLY

1,075.18

+0.27%↑

JNJ

207.23

+0.6%↑

ABBV

227.72

+0.26%↑

UNH

325.11

-0.71%↓

AZN

91.53

+0.2%↑

LLY

1,075.18

+0.27%↑

JNJ

207.23

+0.6%↑

ABBV

227.72

+0.26%↑

UNH

325.11

-0.71%↓

AZN

91.53

+0.2%↑

LLY

1,075.18

+0.27%↑

JNJ

207.23

+0.6%↑

ABBV

227.72

+0.26%↑

UNH

325.11

-0.71%↓

AZN

91.53

+0.2%↑

LLY

1,075.18

+0.27%↑

JNJ

207.23

+0.6%↑

ABBV

227.72

+0.26%↑

UNH

325.11

-0.71%↓

AZN

91.53

+0.2%↑

Strona główna・Stock List・Ascendis Pharma A-S ADR

Ascendis Pharma A-S ADR

Closed

SectorHealthcare

209.37 5.28

Buy Sell

Overview

Share price change

24h

Current

Min

198.04

Max

210.15

Key metrics
By Trading Economics
Income	-22M -61M
Sales	56M 214M
Profit margin	-28.549
Employees	1,017
EBITDA	-56M -53M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+30.24% upside

Market Stats
By TradingEconomics
Market Cap	1.2B 13B
Previous open	204.09
Previous close	209.37

News Sentiment

By Acuity

50%

166 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

157.66 / 167.29 Support & Resistance

Ascendis Pharma A-S ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

22 gru 2025, 23:54 UTC

Major Market Movers

Novo Nordisk ADRs Gain on FDA Approval of First GLP-1 in Pill Form

22 gru 2025, 19:08 UTC

Acquisitions, Mergers, Takeovers

Correction to Alphabet to Buy Intersect Article

22 gru 2025, 17:21 UTC

Acquisitions, Mergers, Takeovers

Alphabet to Buy Intersect for $4.75 Billion as AI-Investment Plans Grow -- Update

22 gru 2025, 16:46 UTC

Acquisitions, Mergers, Takeovers

Alphabet to Buy Intersect for $4.75 Billion in Cash

22 gru 2025, 23:50 UTC

Market Talk

Nikkei May Decline as Yen Rebounds -- Market Talk

22 gru 2025, 23:42 UTC

Market Talk

Gold Hits Record High Amid Rising Geopolitical Risks -- Market Talk

22 gru 2025, 22:31 UTC

Earnings

Zhejiang Sanhua Intelligent Controls: Higher Demand for Air-Conditioning Components Supported Results >002050.SZ

22 gru 2025, 22:31 UTC

Earnings

Zhejiang Sanhua Intelligent Controls: Higher Demand for Refrigeration Supported Results >002050.SZ

22 gru 2025, 22:30 UTC

Earnings

Zhejiang Sanhua Intelligent Controls Sees 2025 Net CNY3.87B, Up 25% on Year >002050.SZ

22 gru 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

22 gru 2025, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

22 gru 2025, 21:37 UTC

Acquisitions, Mergers, Takeovers

Capricorn: Project Is Contiguous to Capricorn's Golden Range, Fields Find Tenure

22 gru 2025, 21:36 UTC

Acquisitions, Mergers, Takeovers

Capricorn to Pay A$500,000 Cash, A$4M in New Shares

22 gru 2025, 21:35 UTC

Acquisitions, Mergers, Takeovers

Capricorn to Acquire Prospective Package From Tempest Minerals

22 gru 2025, 21:35 UTC

Acquisitions, Mergers, Takeovers

Capricorn Metals to Buy Yalgoo Project Tenement Package for A$4.5M

22 gru 2025, 20:54 UTC

Acquisitions, Mergers, Takeovers

Middle West Partners Buys Paul Stuart From Mitsui & Co.

22 gru 2025, 20:52 UTC

Acquisitions, Mergers, Takeovers

HCL Technologies: HCLSoftware to Acquire Jaspersoft From Cloud Software Group >532281.BY

22 gru 2025, 20:09 UTC

Market Talk

U.S. Natural Gas Settles Lower in Choppy Trade -- Market Talk

22 gru 2025, 19:56 UTC

Market Talk

Crude Gains as U.S. Increases Actions Against Venezuela -- Market Talk

22 gru 2025, 19:49 UTC

Acquisitions, Mergers, Takeovers

A Topsy-Turvy Year for Oracle and the Ellisons Will Bleed into 2026 -- Barrons.com

22 gru 2025, 19:23 UTC

Market Talk

Mexico's Inflation Seen Easing in Early December -- Market Talk

22 gru 2025, 19:23 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

22 gru 2025, 19:02 UTC

Market Talk

Global Energy Roundup: Market Talk

22 gru 2025, 19:02 UTC

Market Talk

Precious Metals Climb to New Heights -- Market Talk

22 gru 2025, 18:45 UTC

Market Talk

Canadian Trade-Exposed Industries At Forefront of Job Weakness -- Market Talk

22 gru 2025, 18:30 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Intersect Selling Portion of Assets as Part of Alphabet Deal -- Market Talk

22 gru 2025, 18:23 UTC

Acquisitions, Mergers, Takeovers

What Yogi Berra Would Say About the Talks to Take Over Warner Bros. Discovery -- Barrons.com

22 gru 2025, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

22 gru 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

22 gru 2025, 17:06 UTC

Acquisitions, Mergers, Takeovers

Alphabet to Buy Intersect for $4.75B as AI-Investment Plans Grow -- Update

Peer Comparison

Price change

Ascendis Pharma A-S ADR Forecast

Price Target

By TipRanks

30.24% upside

12 Months Forecast

Average 260.46 USD 30.24%

High 325 USD

Low 220 USD

Based on 14 Wall Street analysts offering 12 month price targets forAscendis Pharma A-S ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

14 ratings

Buy

Hold

Sell

Based on 14 analysts giving stock ratings to Ascendis Pharma A-S ADR - Dist in the past 3 months.

Technical Score

By Trading Central

157.66 / 167.29Support & Resistance

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

166 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.